NASDAQ:ASLN ASLAN PHARMACEU/ADR Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ASLAN PHARMACEU/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.50 -0.03 (-1.97 %) (As of 09/21/2020 12:00 AM ET) Add Compare Share Today's Range$1.46Now: $1.50▼$1.5450-Day Range$1.41MA: $1.55▼$1.6752-Week Range$0.35Now: $1.50▼$8.18Volume22,436 shsAverage Volume172,163 shsMarket Capitalization$47.92 millionP/E RatioN/ADividend YieldN/ABeta2.95 ProfileAnalyst RatingsChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4. Its Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer. It is also conducting a Phase II/III clinical trial of varlitinib for gastric cancer; and testing in a single-arm pivotal clinical trial in biliary tract cancer in China. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. It has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL Limited. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingASLAN PHARMACEU/ADR has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.33, ASLAN PHARMACEU/ADR has a forecasted upside of 323.6% from its current price of $1.50.Amount of Analyst CoverageASLAN PHARMACEU/ADR has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesASLAN PHARMACEU/ADR has received 170 “outperform” votes. (Add your “outperform” vote.)Underperform VotesASLAN PHARMACEU/ADR has received 199 “underperform” votes. (Add your “underperform” vote.)Community SentimentASLAN PHARMACEU/ADR has received 53.93% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ASLAN PHARMACEU/ADR and other stocks. Vote “Outperform” if you believe ASLN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ASLN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldASLAN PHARMACEU/ADR does not currently pay a dividend.Dividend GrowthASLAN PHARMACEU/ADR does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ASLAN PHARMACEU/ADR insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 10.89% of the stock of ASLAN PHARMACEU/ADR is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ASLAN PHARMACEU/ADR are expected to decrease in the coming year, from ($0.42) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ASLAN PHARMACEU/ADR is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ASLAN PHARMACEU/ADR is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.13 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASLN Previous Symbol CUSIPN/A CIKN/A Webwww.aslanpharma.com Phone65-6222-4235Debt Debt-to-Equity RatioN/A Current Ratio3.23 Quick Ratio3.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3 million Price / Sales15.97 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-74.76Profitability EPS (Most Recent Fiscal Year)($0.74) Net Income$-47,020,000.00 Net MarginsN/A Return on Equity-10,427.34% Return on Assets-84.24%Miscellaneous EmployeesN/A Outstanding Shares32,050,000Market Cap$47.92 million Next Earnings Date10/29/2020 (Estimated) OptionableNot Optionable $1.50 -0.03 (-1.97 %) (As of 09/21/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ASLN News and Ratings via Email Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter. ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Frequently Asked Questions How has ASLAN PHARMACEU/ADR's stock been impacted by COVID-19? ASLAN PHARMACEU/ADR's stock was trading at $1.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ASLN stock has decreased by 6.0% and is now trading at $1.4952. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of ASLAN PHARMACEU/ADR? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEU/ADR in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ASLAN PHARMACEU/ADR. When is ASLAN PHARMACEU/ADR's next earnings date? ASLAN PHARMACEU/ADR is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020. View our earnings forecast for ASLAN PHARMACEU/ADR. How were ASLAN PHARMACEU/ADR's earnings last quarter? ASLAN PHARMACEU/ADR (NASDAQ:ASLN) announced its earnings results on Monday, July, 13th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.01. View ASLAN PHARMACEU/ADR's earnings history. What price target have analysts set for ASLN? 3 equities research analysts have issued twelve-month price targets for ASLAN PHARMACEU/ADR's stock. Their forecasts range from $5.00 to $8.00. On average, they expect ASLAN PHARMACEU/ADR's share price to reach $6.33 in the next year. This suggests a possible upside of 323.6% from the stock's current price. View analysts' price targets for ASLAN PHARMACEU/ADR. Who are some of ASLAN PHARMACEU/ADR's key competitors? Some companies that are related to ASLAN PHARMACEU/ADR include Ampio Pharmaceuticals (AMPE), Evofem Biosciences (EVFM), Cerecor (CERC), Avenue Therapeutics (ATXI), OptiNose (OPTN), Alpine Immune Sciences (ALPN), BIOFRONTERA AG/ADR (BFRA), LifeVantage (LFVN), Eton Pharmaceuticals (ETON), Theratechnologies (THTX), Theratechnologies (THERF), Chimerix (CMRX), CorMedix (CRMD), Otonomy (OTIC) and TAIWAN LIPOSOME/S (TLC). View all competitors. What other stocks do shareholders of ASLAN PHARMACEU/ADR own? Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN PHARMACEU/ADR investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (atnm), Onconova Therapeutics (ONTX), Opko Health (OPK), SCYNEXIS (SCYX), AC Immune (ACIU) and Aclaris Therapeutics (ACRS). Who are ASLAN PHARMACEU/ADR's key executives? ASLAN PHARMACEU/ADR's management team includes the following people: Dr. Carl Alan Jason Morton Firth, Chairman & CEO (Age 46)Mr. Kiran Asarpota, VP of Fin. (Age 40)Charlie Hsu, Investor Relations DirectorMr. Ben Goodger, Gen. Counsel (Age 56)Chi-Chin Wang, IR & Corp. Devel. Director When did ASLAN PHARMACEU/ADR IPO? (ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers. What is ASLAN PHARMACEU/ADR's stock symbol? ASLAN PHARMACEU/ADR trades on the NASDAQ under the ticker symbol "ASLN." How do I buy shares of ASLAN PHARMACEU/ADR? Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ASLAN PHARMACEU/ADR's stock price today? One share of ASLN stock can currently be purchased for approximately $1.50. How big of a company is ASLAN PHARMACEU/ADR? ASLAN PHARMACEU/ADR has a market capitalization of $47.92 million and generates $3 million in revenue each year. The company earns $-47,020,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. What is ASLAN PHARMACEU/ADR's official website? The official website for ASLAN PHARMACEU/ADR is www.aslanpharma.com. How can I contact ASLAN PHARMACEU/ADR? ASLAN PHARMACEU/ADR's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
